Providence researcher in the news: a promising treatment for kidney disease

January 11, 2024

Share this Article
Facebook

A study led by Providence doctor and researcher Katherine Tuttle, MD, FACP, of Spokane, Washington is in the news thanks to findings around a promising treatment for kidney disease. Results from the phase II trial revealed the potential of the drug BI 690517 in treating chronic kidney disease, paving the way for a larger phase III trial led by Oxford Nuffield Department of Population Health in England.

Findings from the trial were published in the high-impact peer-reviewed medical journal, The Lancet

Read the media coverage via the links below

On par with the biggest breakthroughs in medicine - Spokesman-Review & Seattle Times
Spokane doctor’s breakthrough kidney disease treatment shows promising results - KXLY News
Outsize benefit seen in trial of drug for kidney disease - UW Medicine Newsroom
Scientists find promising new drug for chronic kidney disease - Knowridge

Studies address need for more treatment options in endometrial cancer and AML

New study evaluates immunotherapy in combination with other medications in people with endometrial cancer, ...

Promising results of amivantamab studies appear in high-profile journals

New articles co-authored by Dr. Rachel Sanborn feature amivantamab studies for people with NSCLC.

Other content in this Stream

Hope comes in a clinical trial: Brad’s remarkable story

Providence researcher in the news: a promising treatment for kidney disease

Previous Article

Next Article

Other content in this Stream

When Brad’s medullary thyroid cancer returned after a surgical procedure, he enrolled in a clinical trial. Now, his cancer is nearly undetectable.

After facing a life-altering brain tumor, this Providence Swedish patient discovered clarity, gratitude, and a mission to support the research that guided her care.

Learn how the Providence Montana Heart Institute is working to bring world-class clinical research and the latest heart care and treatment options closer to Montana communities.

The goal is to create a digital representation—or medical twin—of a patient and use advanced AI to understand what treatments work best and provide more informed options about the most effective paths

New radiation safety research from Providence CARDS and Providence Heart Institute of Oreogn could help bring more women into interventional cardiology

PSNI collaborates with Seattle-based HDT Bio on preparations for trialing novel treatment to breach blood-brain barrier

Published in JAMA Network Open, a new Providence study uses real-world data to show how AI ambient listening reduces documentation burden, improving efficiency and clinician focus on patient care.

Based on research around the innovative Hawk's Eye Apartments project in Clatsop County, Oregon, Providence CORE offers five key takeaways for healthcare investments in affordable workforce housing.

Providence researchers conducted over 1500 studies in 2025, according to a new report from the Providence Research Network. Check out the 2025 research program brief to learn more!

Inside the IMA203 phase III trial enrolling patients at Providence Cancer Institute.

Providence is joining a nationwide, federally funded research project to develop a Large Health Behavior Model.

Providence cancer researchers will use a $3.4-million federal grant to study why a new treatment regimen is showing better outcomes against tumors that have been difficult to treat in the past.

Radiation exposure during TAVR procedures was low overall across nearly 9,000 cases performed at Providence from 2018 to 2022, according to a new Providence study.

A new Providence study identifies barriers to colorectal cancer screening among racially diverse communities and is helping to shape outreach efforts to improve screening rates.

A new study focused on stories will change health outcomes for Black women.

A new medication called M3T01, developed at Providence Cancer Institute, takes a different approach to immunotherapy.

New research from CORE and Providence Genomics asks whether how and where genetic testing is offered affects whether patients say “yes.”

The annual AACR meeting draws the most innovative cancer researchers seeking breakthroughs in treatments.

This study is now enrolling patients at Providence Cancer Institute – the only site outside of Australia.